David Tsao

Company: BillionToOne

Job title: Co-founder & Chief Technology Officer

Seminars:

Optimizing Tissue-free ctDNA Evaluations with QCT Technology: Enhancing Sensitivity for Therapy Selection & Enabling Quantitative Therapy Response Monitoring 12:00 pm

Employing our patented QCT technology to achieve single molecule resolution  Enhanced limit of detection augments sensitivity in low-VAF setting to improve detection of clinically actionable alterations Precise therapy Response quantification and clonal profiling through a personalized methylation-based approach Read more

day: Day Two Track B (AM)